Efficacity of Weekly Paclitaxel in Association or Not With Bevacizumab in Metastatic or Locally Advanced Angiosarcomas

Inclusion Criteria: * Angiosarcoma histologically proven * Metastatic or locally advanced and not accessible to surgery treatment * Measurable tumor with at least 1 measurable lesion, according to RECIST * For angiosarcoma in irradiated region, absence of clinical arguments of progression of the tumor prior treated by radiation * At least 28 days since the previous treatment (systemic or major surgery) * Performance Status (ECOG) ≤ 1 * Man or woman \>= 18 years * Polynuclear neutrophils \>1500/mm3, platelets \> 100 000/ mm3, Hemoglobin \> 9.0 g/dl * Total bilirubin ≤ 1.5 x USL, AST and ALT ≤ 2.5 x USL (or ≤ 5 if hepatic metastasis ) * Serum creatinin ≤ 1.5 x USL or clearance calculated \> 50 ml/mn (Cockcroft formulae) * Absence of hematuria on dipstick * Proteinuria on dipstick \<2+, if \>2, the 24 hours proteinuria must be \< 1g * Albumin \> 35 g/l and lymphocytes \> 700/mm3 attesting a life expectancy \> 3 months * Normal cardiac function : LVEF ≥ 50% * Normal coagulation test : INR ≤ 1.5 and TCA ≤ 1.5 x USL within 7 days before inclusion * Systolic BP ≤ 150 mmHg and diastolic BP ≤ 100 mmHg * Negative pregnancy test for women of reproductive potential(within 7 days before treatment start) * Effective contraceptive methods for male and female (if applicable) during the period of treatment and until the 6 months after the last administration of Bevacizumab * Adequate central veinous access * Patient covered by government health insurance * Informed consent form signed by the patient Exclusion Criteria: * Patients that have received more than 2 regimens of chemotherapy whatever the indication * Kaposi's sarcoma, hemangio-endothelioma, hemangio-pericytoma (Malignant solitary fibrous tumor) * Surgery (except the diagnostic biopsy) or radiotherapy within the past 4 weeks before inclusion, except antalgic radiotherapy * Uncontrolled, active peptic ulcer, * Other malignant evolutive tumor * Previous thrombotic or hemorrhagic disorders * Clinically significant cardiovascular disease (stroke within 6 months prior inclusion, unstable angina, heart failure, myocardial infarction, arrhythmia requiring treatment) * Anticoagulant treatment for curative aim within 10 days before beginning of treatment (oral or parenteral administration), aspirin \> 325 mg/day, or Plavix or a thrombolytic (thrombolytics for preventive use is permitted) or anti-platelet (dipyridamol, ticlopidine, clodiprogel, cilostazol) * Chronic treatment(more than 15 days) by every AINS including aspirin \> 325 mg/j * Currently active bacterial or fungus infection (grade \> 2 CTCAE v4.02) * Known HIV1, HIV2, hepatitis B or hepatitis C infections * Presence of known meningeal or brain metastasis * Epilepsy requiring the use of anti-epileptic * Previous organ transplant * Peripheral stem cell transplantation within 4 months prior to inclusion in the study * Using of drugs affecting the biological response, for example G-CSF, within the 3 weeks before inclusion * Kidney dialysis patient * Clinically significant neuropathy (grade\> 2 CTCAE V4.02) * Any circumstance that could jeopardise compliance or proper follow-up during the trial * Pregnant or nursing women. Women should not breastfeed for at least 6 months after the last administration of Bevacizumab * Constitutional or acquired coagulopathy * Uncontrolled hypertension (SBP\> 150 mmHg or DBP\> 100 mmHg) * Known hypersensitivity to paclitaxel or to one of its excipients (Cremophor EL, to Bevacizumab components, to products of Chinese hamster ovary cells (CHO) or other recombinant human or humanized antibodies * Patients unable to undergo trail medical follow-up for geographical, social or psychological reasons * Patient refusal of ambulatory care